Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | SMOX | Q9NWM0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611639 | 0.96 | ADRB2 (0.34) | ADRB2ADRB1TSHRALDH1A1PAOX | |
| SCHEMBL5611699 | 0.96 | ADRB2 (0.34) | ADRB2ADRB1TSHRALDH1A1PAOX | |
| SCHEMBL3023756 | 0.86 | PAOX (0.50) | ALDH1A1PAOXSMOX | |
| SCHEMBL1948513 | 0.86 | KDM1A (0.43) | TSHRALDH1A1PAOXSMOXSMN1; SMN2 | |
| SCHEMBL20038043 | 0.85 | — | — | |
| SCHEMBL3312976 | 0.85 | — | — | |
| SCHEMBL22105 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL3009329 | 0.83 | KDM1A (0.46) | TSHRALDH1A1PAOXSMOXSMN1; SMN2 | |
| SCHEMBL9993563 | 0.83 | — | — | |
| SCHEMBL13650833 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 765 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3718551-B1 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | RENOSIS INC (US) | 2026-02-04 | — | — | EP | claimed |
| CN-111671767-B | Proton-binding polymers for oral administration | 特里赛达公司 | 2024-03-08 | — | — | CN | claimed |
| CN-116211887-A | Composition for treating acid-base imbalance | 特里赛达公司 | 2023-06-06 | — | — | CN | claimed |
| EP-3993763-A1 | FATTY ACID POLYGLYCERYL ESTER-CONTAINING CLEANSING PREPARATION | Beiersdorf AG (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-3415662-B1 | A METHOD FOR PRODUCING AN IONIC LIQUID | VITO NV (BE) | 2022-01-12 | — | — | EP | claimed |
| US-11197887-B2 | Proton-binding polymers for oral administration | TRICIDA, INC. (US) | 2021-12-14 | — | — | US | claimed |
| US-20210205351-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2021-07-08 | — | — | US | claimed |
| EP-3831395-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | Tricida Inc. (US) | 2021-06-09 | — | — | EP | claimed |
| CN-107641174-B | Copper (II) ion surface imprinted polymer with double exchange of anions and cations and preparation method thereof | 淮海工学院 | 2021-03-12 | — | — | CN | claimed |
| WO-2021004711-A1 | FATTY ACID POLYGLYCERYL ESTER-CONTAINING CLEANSING PREPARATION | BEIERSDORF AG (DE) | 2021-01-14 | — | — | WO | claimed |
| US-5872260-A | High purity 1,3-dialkyl-2-imidazolidinone and preparation process of same | MITSUI CHEMICALS, INC. (JP) | 1999-02-16 | — | — | US | claimed |
| EP-0823427-A1 | High purity 1,3-dialkyl-2-imidazolidinone and preparation process of same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1998-02-11 | — | — | EP | claimed |
| EP-0526334-B1 | Electroless palladium plating composition | OKUNO CHEM IND CO (JP) | 1998-01-21 | — | — | EP | claimed |
| EP-0428366-B1 | Method for introducing a 1,2 double bond into azasteroids | MERCK & CO INC (US) | 1995-09-20 | — | — | EP | claimed |
| US-5292361-A | Hypophosphite, ammonia or alkylamine, polyethyleneimine, aliphatic alkylamine | OKUNO CHEMICAL INDUSTRIES CO., LTD. (JP) | 1994-03-08 | — | — | US | claimed |
| EP-0526334-A2 | Electroless palladium plating composition | OKUNO CHEMICAL INDUSTRIES CO. LTD (JP) | 1993-02-03 | — | — | EP | claimed |
| EP-0198345-B1 | PROCESS FOR PRODUCING 1,3-DIALKYL-2-IMIDAZOLIDINONE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-08-01 | — | — | EP | claimed |
| EP-0264261-A2 | Preparation of N-substituted piperazinones | THE DOW CHEMICAL COMPANY (US) | 1988-04-20 | — | — | EP | claimed |
| US-4731453-A | Process for producing 1, 3-dialkyl-2-imidazolidinone | MITSUI TOATSU CHEMICALS, INC. (JP) | 1988-03-15 | — | — | US | claimed |
| EP-0198345-A1 | Process for producing 1,3-dialkyl-2-imidazolidinone | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1986-10-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205351-A1 | COMPOSITIONS FOR TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SLC26A3 | ADRB2 2971/4885ADRB1 3415/4885TSHR 2261/4885 |
| US-11197887-B2 | Proton-binding polymers for oral administration | SLC9A1, HRH2, SLC9A2 | ADRB2 4338/4885ADRB1 4371/4885TSHR 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.